Alpha Tau Medical Ltd. (DRTS)
Alpha Tau Medical Ltd. (DRTS) Stock Price, Analysis & Data
| Bid | 10.3 |
| Market Cap | 1.23B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -92.57M |
| Beta | 1.19 |
| EPS (ttm) | -0.67 |
| PE Ratio (ttm) | n/a |
| Forward PE | -25.91 |
| P/B (ttm) | 17.75 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 19, 2026 |
| Ask | 17.3 |
| Volume | 299,181 |
| Avg. Volume (20D) | 832,891 |
| Open | 14.38 |
| Previous Close | 14.27 |
| Day's Range | 13.41 - 14.40 |
| 52-Week Range | 3.00 - 14.40 |
| Analyst | Buy |
| Price Target | 15 (9.89%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DRTS
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The ...
Financial Performance
In 2025, Alpha Tau Medical's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -42.63M, an increase of 34.26%.
Financial StatementsAnalyst Forecast
According to 5 analyst ratings, the average rating for DRTS stock is "Buy". The 12-month stock price forecast is 15, which is upside of 9.89% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
